✦ LIBER ✦

PCNI3 COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-GEMCYTABINE

✍ Scribed by A Skowron; J Brandys

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of paclitaxel plus ci

✍ Earle, C C; Evans, W K 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 84 KB

Pharmacoeconomic analysis of advanced no

✍ C. Rubio-Terrés; J.L. Tisaire; S. Kobina; A. Moyano 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 351 KB

PCNI6 COMPARATIVE COSTS OF GEMCITABINE/C

✍ H Bischoff; M Hamann; G Stynes; S Bhalla; D Tilden; A Kielhorn 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Treatment of advanced non-small cell lun

✍ Almodovar, M; Dionisio, J; Matias, D; Duro da Costa, J 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

A randomized comparison of cisplatin-vin

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 166 KB

PCN13: PHARMACOECONOMIC ANALYSIS OF ADVA

✍ C Rubio Terrés; JL Tisaire; S Kobina; A Moyano 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB